title: Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial.
abstract: BACKGROUND
  Cholera is a major public-health problem, with children most affected. However, effective single-dose antimicrobial regimens have been identified only for adults. Our aim was to compare the efficacy of azithromycin and erythromycin regimens in the treatment of children.
  
  
  METHODS
  We did a double-blind, randomised study of 128 severely dehydrated children (age 1-15 years) with cholera, treated at one of two treatment centres in Bangladesh in 1999. Children were assigned single-dose azithromycin (20 mg/kg bodyweight, maximum individual dose 1 g; n=65) or 12.5 mg/kg erythromycin (maximum dose 500 mg; n=63) every 6 h for 3 days. Patients stayed in hospital for 5 days. We measured fluid balance every 6 h, and obtained a rectal swab or stool sample for culture daily. Our primary outcome measures were clinical success of treatment-ie, cessation of watery diarrhoea within 48 h-and bacteriological success-ie, absence of Vibrio cholerae O1 or O139 from cultures of stool or rectal swab samples after study day 2. Analysis was per protocol.
  
  
  RESULTS
  Two children in both groups withdrew from the study, and we excluded one child in the erythromycin group. Treatment was clinically successful in 48 (76%) patients who received azithromycin and 39 (65%) who received erythromycin (difference 11%, 95% CI -5 to 27, p=0.244); and bacteriologically successful in 45 (71%) and 49 (82%) patients, respectively (10%, -5 to 25, p=0.261). Patients treated with azithromycin had a shorter duration of diarrhoea (median 24 h vs 42 h; difference 12 h, 0-18 h, p=0.019) and fewer episodes of vomiting (1 vs 4; difference 1 episode, 0-3 episodes, p=0.023).
  
  
  CONCLUSIONS
  Single-dose azithromycin is as effective for treatment of cholera in children as standard erythromycin therapy, but is associated with less vomiting.
authors.affiliation: Clinical Sciences Division, International Centre For Diarrhoeal Disease Research, Bangladesh, Dhaka. wakhan@icddrb.org
authors.forename: Wasif A
authors.initials: WA
authors.lastname: Khan
authors.forename: Debasish
authors.initials: D
authors.lastname: Saha
authors.forename: Anisur
authors.initials: A
authors.lastname: Rahman
authors.forename: Mohammed A
authors.initials: MA
authors.lastname: Salam
authors.forename: Joseph
authors.initials: J
authors.lastname: Bogaerts
authors.forename: Michael L
authors.initials: ML
authors.lastname: Bennish
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017963:Azithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001459:Bangladesh; D002648:Child; D002675:Child, Preschool; D002771:Cholera / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005243:Feces / Q000382:microbiology*; D006801:Humans; D007223:Infant; D008297:Male; D016896:Treatment Outcome; D041241:Vibrio cholerae O1 / Q000302:isolation & purification* / Q000472:pathogenicity; D041242:Vibrio cholerae O139 / Q000302:isolation & purification* / Q000472:pathogenicity
chemical_list: D000900:Anti-Bacterial Agents; D004917:Erythromycin; D017963:Azithromycin